Methionine aminopeptidases as potential targets for treatment of gastrointestinal cancers and other tumors

Current Drug Targets

Volumn 11, Issue 11, 2010, Pages 1439-1457

  Mauriz, José L ^a   Martín Renedo, Javier ^a   García Palomo, Andrés ^b   Tuñón, María J ^a   González Gallego, Javier ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Hospital of Leon   (Spain)

Author keywords

Angiogenesis; Cancer; Methionine aminopeptidase; Proliferation

Indexed keywords

A 357300; A 800141; CASPASE 2; CASPASE 7; CASPASE 9; CYCLIN D; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DOCETAXEL; FLUOROURACIL; FR 118487; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; METHIONYL AMINOPEPTIDASE; METHIONYL AMINOPEPTIDASE 1D; METHIONYL AMINOPEPTIDASE 2; NC2213; PPI 2458; RAC1 PROTEIN; SCATTER FACTOR; TELOMERASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN; AMINOPEPTIDASE; ANGIOGENESIS INHIBITOR; CYCLOHEXANE DERIVATIVE; ENZYME INHIBITOR; SESQUITERPENE; UNSATURATED FATTY ACID;

ANAPLASTIC THYROID CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL ADHESION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISTANT METASTASIS; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; IC 50; KAPOSI SARCOMA; KIDNEY CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MYRISTYLATION; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; THYROID CANCER; TUMOR GROWTH; UTERINE CERVIX CANCER; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; GASTROINTESTINAL TUMOR; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

AMINOPEPTIDASES; ANGIOGENESIS INHIBITORS; ANIMALS; CYCLOHEXANES; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES;

EID: 79955047006     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011439     Document Type: Review

References (153)

1. Lowther WT, Matthews BW. Structure and function of the methionine aminopeptidases. Biochim Biophys Acta 2000; 1477: 157-67.
2. Endo H, Takenaga K, Kanno T, Satoh H, Mori S. Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4. J Biol Chem 2002; 277: 26396-402.
3. Bradshaw RA, Brickey WW, Walker KW. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem Sci 1998; 23: 263-7.
4. Ray MK, Datta B, Chakraborty A, Chattopadhyay A, Meza-Keuthen S, Gupta NK. The eukaryotic initiation factor 2-associated 67-kDa polypeptide (p67) plays a critical role in regulation of protein synthesis initiation in animal cells. Proc Natl Acad Sci USA 1992; 89: 539-43.
5. Datta B, Ray MK, Chakrabarti D, Wylie DE, Gupta NK. Glycosylation of eukaryotic peptide chain initiation factor 2 (eIF-2)-associated 67-kDa polypeptide (p67) and its possible role in the inhibition of eIF-2 kinase-catalyzed phosphorylation of the eIF-2 alpha-subunit. J Biol Chem 1989; 264: 20620-4.
6. Giglione C, Serero A, Pierre M, Boisson B, Meinnel T. Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J 2000; 19: 5916-29.
7. Chang SY, McGary EC, Chang S. Methionine aminopeptidase gene of Escherichia coli is essential for cell growth. J Bacteriol 1989; 171: 4071-2.
8. Chang YH, Teichert U, Smith JA. Molecular cloning, sequencing, deletion, and overexpression of a methionine aminopeptidase gene from Saccharomyces cerevisiae. J Biol Chem 1992; 267: 8007-11.
9. Li X, Chang YH. Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc Natl Acad Sci USA 1995; 92: 12357-61.
10. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000; 77: 465-73.
11. Li X, Chang YH. Evidence that the human homologue of a rat initiation factor-2 associated protein (p67) is a methionine aminopeptidase. Biochem Biophys Res Commun 1996; 227: 152-9.
12. Dummitt B, Micka WS, Chang YH. N-terminal methionine removal and methionine metabolism in Saccharomyces cerevisiae. J Cell Biochem 2003; 89: 964-74.
13. Hu X, Addlagatta A, Lu J, Matthews BW, Liu JO. Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. Proc Natl Acad Sci USA 2006; 103: 18148-53.
14. Leszczyniecka M, Bhatia U, Cueto M, et al. MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer. Oncogene 2006; 25: 3471-8.
15. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 2001; 159: 721-31.
16. Kanno T, Endo H, Takeuchi K, Morishita Y, Fukayama M, Mori S. High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts. Lab Invest 2002; 82: 893-901.
17. Matsuzawa T, Hatsugai M, Moriguchi K. Increase of methionine aminopeptidase activity in hyperplastic Leydig cells of rat cryptorchid testis: a histochemical study. J Vet Med Sci 1992; 54: 1157-63.
18. Wang J, Sheppard GS, Lou P, et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res 2003; 63: 7861-9.
19. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 2000; 97: 6427-32.
20. Roderick SL, Matthews BW. Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: a new type of proteolytic enzyme. Biochemistry 1993; 32: 3907-12.
21. Lowther WT, Orville AM, Madden DT, Lim S, Rich DH, Matthews BW. Escherichia coli methionine aminopeptidase: implications of crystallographic analyses of the native, mutant, and inhibited enzymes for the mechanism of catalysis. Biochemistry 1999; 38: 7678-88.
22. Arfin SM, Kendall RL, Hall L, Weaver LH, Stewart AE, Matthews BW. Eukaryotic methionyl aminopeptidases: two classes of cobaltdependent enzymes. Proc Natl Acad Sci USA 1995; 92: 7714-8.
23. Vetro JA, Chang YH. Yeast methionine aminopeptidase type 1 is ribosome-associated and requires its N-terminal zinc finger domain for normal function in vivo. J Cell Biochem 2002; 85: 678-88.
24. Zuo S, Guo Q, Ling C, Chang YH. Evidence that two zinc fingers in the methionine aminopeptidase from Saccharomyces cerevisiae are important for normal growth. Mol Gen Genet 1995; 246: 247-53.
25. Li JY, Chen LL, Cui YM, et al. Characterization of full length and truncated type I human methionine aminopeptidases expressed from Escherichia coli. Biochemistry 2004; 43: 7892-8.
26. Ben-Bassat A, Bauer K, Chang SY, Myambo K, Boosman A, Chang SJ. Processing of the initiation methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J Bacteriol 1987; 169: 751-7.
27. Sato Y. Role of aminopeptidase in angiogenesis. Biol Pharm Bull 2004; 27: 772-6.
28. Walker KW, Bradshaw RA. Yeast methionine aminopeptidase I can utilize either Zn2+ or Co2+ as a cofactor: a case of mistaken identity? Protein Sci 1998; 7: 2684-7.
29. Wang J, Sheppard GS, Lou P, et al. Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese. Biochemistry 2003; 42: 5035-42.
30. Miller CG, Strauch KL, Kukral AM, et al. N-terminal methioninespecific peptidase in Salmonella typhimurium. Proc Natl Acad Sci USA 1987; 84: 2718-22.
31. Chang SYP, McGary EC, Chang S. Methionine aminopeptidase gene of Escherichia coli is essential for cell growth. J Bacteriol 1989; 171: 4071-2.
32. Solbiati J, Chapman-Smith A, Miller JL, Miller CG, Cronan JE. Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal. J Mol Biol 1999; 290: 607-14.
33. D'souza VM, Bennett B, Copik AJ, Holz RC. Divalent metal binding properties of the methionyl aminopeptidase from Escherichia coli. Biochemistry 2000; 39: 3817-26.
34. Tsunasawa S, Stewart JW, Sherman F. Amino-terminal processing of mutant forms of yeast iso-1-cytochrome c. The specificities of methionine aminopeptidase and acetyltransferase. J Biol Chem 1985; 260: 5382-91.
35. Moerschell RP, Hosokawa Y, Tsunasawa S, Sherman F. The specificities of yeast methionine aminopeptidase and acetylation of amino-terminal methionine in vivo. Processing of altered iso-1-cytochromes c created by oligonucleotide transformation. J Biol Chem 1990; 265: 19638-43.
36. Huang S, Elliot RC, Liu PS, et al. Specificity of cotranslational amino-terminal processing of proteins in yeast. Biochemistry 1987; 26: 8242-6.
37. Hirel PH, Schmitter JM, Dessen P, Fayat G, Blanquet S. Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid. Proc Natl Acad Sci USA 1989; 86: 8247-51.
38. Walker KW, Bradshaw RA. Yeast methionine aminopeptidase I. Alteration of substrate specificity by site-directed mutagenesis. J Biol Chem 1999; 274: 13403-9.
39. Frottin F, Martinez A, Peynot P, et al. The proteomics of Nterminal methionine cleavage. Mol Cell Proteom 2006; 5: 2336-49.
40. Jørgensen AT, Norrby PO, Liljefors TJ. Investigation of the metal binding site in methionine aminopeptidase by density functional theory. J Comput Aided Mol Des 2002; 16: 167-79.
41. Dummitt B, Fei Y, Chang YH. Functional expression of human methionine aminopeptidase type 1 in Saccharomyces cerevisiae. Protein Pept Lett 2002; 9: 295-303.
42. Bernier SG, Taghizadeh N, Thompson CD, Westlin WF, Hannig G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem 2005; 95: 1191-203.
43. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004; 116: 221-34.
44. Page AM, Hieter P. The anaphase-promoting complex: new subunits and regulators. The anaphase-promoting complex: new subunits and regulators. Annu Rev Biochem 1999; 68: 583-609.
45. Ma ZQ, Xie SX, Huang QQ, Nan FJ, Hurley TD, Ye QZ. Structural analysis of inhibition of E. coli methionine aminopeptidase: implication of loop adaptability in selective inhibition of bacterial enzymes. BMC Struct Biol 2007; 7: 84-95.
46. Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T. An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem 2003; 278: 52953-63.
47. Chen S, Vetro JA, Chang YH. The specificity in vivo of two distinct methionine aminopeptidases in Saccharomyces cerevisiae. Arch Biochem Biophys 2002; 398: 87-93.
48. Garrabrant T, Tuman R, Ludovici D, Tominovich R, Simoneaux R, Galemmo R. Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2). Angiogenesis 2004; 7: 91-6.
49. Matheson AT, Yaguchi M, Visentin LP. The conservation of amino acids in the n-terminal position of ribosomal and cytosol proteins from Escherichia coli, Bacillus stearothermophilus, and Halobacterium cutirubrum. Can J Biochem 1975; 53: 1323-7.
50. Saleh MT, Fillon M, Brennan PJ, Belisle JT. Identification of putative exported/secreted proteins in prokaryotic proteomes. Gene 2001; 269: 195-204.
51. Datta B. Roles of P67/MetAP2 as a tumor suppressor. Biochim Biophys Acta 2009; 1796: 281-92.
52. Ron D, Harding HP. elF2α phosphorylation in cellular stress responses and disease. In: Mathews MB, Sonenberg N, Hershey JWB, Eds. Translational control in biology and medicine. Cold Spring Harbor Laboratories Press: New York 2006; pp. 345-68.
53. Datta B, Datta R, Majumdar A, Balusu R. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases. Biochemistry 2004; 43: 14821-31.
54. Datta B, Datta R. Induction of apoptosis due to lowering the level of eukaryotic initiation factor 2-associated protein, p67, from mammalian cells by antisense approach. Exp Cell Res 1999; 246: 376-83.
55. Friedrich I, Ben-Bassat H, Levitzki A. Activation of dsRNA dependent protein kinase PKR in Karpas299 does not lead to cell death. Cancer Biol Ther 2005; 4: 734-9.
56. Datta R, Choudhury P, Ghosh A, Datta B. A glycosylation site, 60SGTS63, of p67 is required for its ability to regulate the phosphorylation and activity of eukaryotic initiation factor 2alpha. Biochemistry 2003; 42: 5453-60.
57. Datta B, Ghosh A, Majumdar R, Datta R. Autoproteolysis of rat p67 generates several peptide fragments: the N-terminal fragment, p26, is required for the protection of eIF2alpha from phosphorylation. Biochemistry 2007; 46: 3465-75.
58. Boxem M, Tsai CW, Zhang Y, Saito RM, Liu JO. The C. elegans methionine aminopeptidase 2 analog map-2 is required for germ cell proliferation. FEBS Lett 2004; 576: 245-50.
59. Yeh JRJ, Ju R, Brdlik CM, et al. Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci USA 2006; 103: 10379-84.
60. Cutforth T, Gaul U. A methionine aminopeptidase and putative regulator of translation initiation is required for cell growth and patterning in Drosophila. Mech Dev 1999; 82: 23-8.
61. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69: 212-6.
62. Antoine N, Greimers, R, De Roanne C, et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 1994; 54: 2073-6.
63. Abe J, Zhou W, Takuwa N, et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclindependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994; 54: 3407-12.
64. Hori A, Ikeyama S, Sudo K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun 1994; 204: 1067-73.
65. Mauriz JL, González-Gallego J. Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. J Pharm Sci 2008; 97: 4129-54.
66. Koyama H, Nishizawa Y, Hosoi M, et al. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. Circ Res 1996; 79: 757-64.
67. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
68. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-9.
69. Iida A, Yamaguchi A, Hirose K. Telomerase activity in colorectal cancer and its relationship to bcl-2 expression. J Surg Oncol 2000; 73: 219-23.
70. Kishimoto K, Fujimoto J, Takeuchi M, Yamamoto H, Ueki T, Okamoto E. Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol 1998; 69: 119-24.
71. Sheen IS, Jeng KS, Jeng WJ, et al. Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis. World J Gastroenterol 2005; 11: 771-7.
72. Bradshaw RA, Yi E. Methionine aminopeptidases and angiogenesis. Essays Biochem 2002; 38: 65-78.
73. Nakagawa H, Koyanagi S, Takiguchi T, et al. 24-hour oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins. Cancer Res 2004; 64: 8328-33.
74. Koyanagi S, Nakagawa H, Kuramoto Y, Ohdo S, Soeda S, Shimeno H. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies. J Pharmacol Exp Ther 2003; 304: 669-74.
75. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett 2009; 280: 15-30.
76. Selvakumar P, Lakshmikuttyamma A, Kanthan R, Kanthan SC, Dimmock JR, Sharma RK. High expression of methionine aminopeptidase 2 in human colorectal adenocarcinomas. Clin Cancer Res 2004; 10: 2771-5.
77. Tucker LA, Zhang Q, Sheppard GS, et al. Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation. Oncogene 2008; 27: 3967-76.
78. Raman R, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100-12.
79. Thiaville MM, Pan YX, Gjymishka A, Zhong C, Kaufman RJ, Kilberg MS. MEK signaling is required for phosphorylation of eIF2alpha following amino acid limitation of HepG2 human hepatoma cells. J Biol Chem 2000; 283: 10848-57.
80. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
81. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 444-7.
82. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-74.
83. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
84. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995; 159: 113-60.
85. Lien WH, Chen CK, Lai LY, et al. Participation of cyclin D1 deregulation in TNP-470-mediated cytostatic effect: involvement of senescence. Biochem Pharmacol 2004; 68: 729-38.
86. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998; 282: 1324-7.
87. Yamamoto T, Sudo K, Fujita T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 1994; 14: 1-3.
88. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001; 28: 80-5.
89. Kurebayashi J, Kurosumi M, Dickson RB, Sonoo H. Angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) inhibits tumor angiogenesis, growth and spontaneous metastasis of MKL-4 human breast cancer cells in female athymic nude mice. Breast Cancer 1994; 1: 109-15.
90. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
91. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998; 338: 991-2.
92. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999; 5: 1989-95.
93. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999; 17: 2541-5.
94. Zukiwski A, Gutterman J, Bui C, et al. Phase 1 trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen independent prostate cancer. Proc Annu Meet Am Assoc Soc Clin Oncol 1994; 13: 795.
95. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16: 1444-9.
96. Hannig G, Lazarus DD, Bernier SG, et al. Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458. Int J Oncol 2006; 28: 955-63.
97. Shi Y, Zou M, Collison K, et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006; 91: 2373-9.
98. Jackson-Grusby L, Swiergel J, Linzer D. A growth-related mRNA in cultured mouse cells encodes a placental calcium binding protein. Nucleic Acids Res 1987; 15: 6677-90.
99. Wang J, Sheppard GS, Lou P, et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res 2003; 63: 7861-9.
100. Wang J, Tucker LA, Stavropoulos J, et al. Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor. Proc Natl Acad Sci USA 2008; 105: 1838-43.
101. Niwano M, Arii S, Mori A, et al. Inhibition of tumor growth and microvascular angiogenesis by the potent angiogenesis inhibitor, TNP-470, in rats. Surg Today 1998; 28: 915-22.
102. Tanaka S, Arii S. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol 2006; 11: 82-9.
103. Mauriz JL, Durán MC, Molpeceres V, et al. Cell-cycle inhibition by TNP-470 in an in vivo model of hepatocarcinoma is mediated by a p53 and p21WAF1/CIP1 mechanism. Transl Res 2007; 149: 46-53.
104. Mauriz JL, Linares P, Macias RI, et al. TNP-470 inhibits oxidative stress, nitric oxide production and nuclear factor kappa B activation in a rat model of hepatocellular carcinoma. Free Radic Res 2003; 37: 841-8.
105. Chun E, Han CK, Yoon JH, Sim TB, Kim YK, Lee KY. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 2005; 114: 124-30.
106. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
107. Sawanyawisuth K, Wongkham C, Pairojkul C, et al. Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target. Acta Oncol 2007; 46: 378-85.
108. Selvakumar P, Lakshmikuttyamma A, Lawman Z, Bonham K, Dimmock JR, Sharma RK. Expression of methionine aminopeptidase 2, N-myristoyltransferase, and N-myristoyltransferase inhibitor protein 71 in HT29. Biochem Biophys Res Commun 2004; 322: 1012-7.
109. Selvakumar P, Lakshmikuttyamma A, Das U, Pati HN, Dimmock JR, Sharma RK. NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells. Mol Cancer 2009; 8: 65-71.
110. Chen T, Yang I, Irby R, et al. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 2003; 63: 4368-74.
111. Ogawa H, Sato Y, Kondo M, et al. Combined treatment with TNP-470 and 5-fluorouracil effectively inhibits growth of murine colon cancer cells in vitro and liver metastasis in vivo. Oncol Rep 2000; 7: 467-72.
112. Hou L, Mori D, Takase Y, Meihua P, Kai K, Tokunaga O. Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis. Pathol Int 2009; 59: 448-61.
113. van Riel JM, Giaccone G, Pinedo HM. Pancreaticobiliary cancer: the future aspects of medical oncology. Pancreaticobiliary cancer: the future aspects of medical oncology. Ann Oncol 1999; 10: 296-9.
114. Hotz HG, Reber JA, Hotz B, et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001; 5: 131-8.
115. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003; 27: 405-11.
116. Ryschich E, Werner J, Gebhard MM, Klar E, Schmidt J. Angiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma. Pancreas 2003; 26: 166-72.
117. Jia L, Zhang MH, Yuan SZ, Huang WG. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 2005; 11: 447-50.
118. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997; 150: 641-51.
119. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72: 619-24.
120. Miyazaki J, Tsuzuki Y, Matsuzaki K, et al. Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer. Int J Cancer 2005; 117: 499-505.
121. Kawarada Y, Ishikura H, Kishimoto T, et al. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas 1997; 15: 251-7.
122. Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998; 89: 963-9.
123. Kato H, Ishikura H, Kawarada Y, et al. Anti-angiogenic treatment for peritoneal dissemination of pancreas adenocarcinoma: a study using TNP-470. Jpn J Cancer Res 2001; 92: 67-73.
124. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1996. CA Cancer J Clin 1996; 46: 5-27.
125. Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 2003; 75: 331-6.
126. Bo H, Ghazizadeh M, Shimizu H, et al. Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis. J Nippon Med Sch 2004; 71: 172-80.
127. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453-64.
128. Poulaki V, Mitsiades CS, McMullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88: 5392-8.
129. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 2004; 145: 1031-8.
130. Nahari D, Satchi-Fainaro R, Chen M, et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther 2007; 6: 1329-37.
131. Van Hennik PB, Hordijk PL. Rho GTPases in hematopoietic cells. Antioxid Redox Signal 2005; 7: 1440-55.
132. van Wetering S, van Buul JD, Quik S, et al. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci 2002; 115: 1837-46.
133. Satchi-Fainaro R, Mamluk R, Wang L, et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005; 7: 251-61.
134. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14: 405-14.
135. Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 2005; 228: 171-9.
136. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-73.
137. Meadows AT, Tsunematsu Y. Late effects of treatment for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, Eds. Neuroblastoma Elsevier Science BV: Amsterdam 2000; pp. 561-70.
138. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000; 60: 712-21.
139. Nagabuchi E, VanderKolk WE, Une Y, Ziegler MM. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 1997; 32: 287-93.
140. Wassberg E, Pahlman S, Westlin JE, Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997; 41: 327-33.
141. Katzenstein HM, Rademaker AW, Senger C, et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999; 5: 4273-78.
142. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001; 7: 977-84.
143. Yoshizawa J, Mizuno R, Yoshida T, et al. Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma. J Surg Res 2000; 93: 82-7.
144. Morowitz MJ, Barr R, Wang Q, et al. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res 2005; 11: 2680-5.
145. Yasuda C, Sakata S, Kakinoki S, Takeyama Y, Ohyanagi H, Shiozaki H. In vivo evaluation of microspheres containing the angiogenesis inhibitor, TNP-470, and the metastasis suppression with liver metastatic model implanted neuroblastoma. Pathophysiology 2009; 17: 149-55.
146. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57.
147. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
148. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 2003; 53: 5233-6.
149. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgenindependent prostate cancer. Clin Cancer Res 2001; 7: 1198-203.
150. Muramaki M, Miyake H, Hara I, Kamidono S. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int J Oncol 2005; 26: 623-8.
151. Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs 2002; 13: 743-9.
152. Cooper AC, Karp RM, Clark EJ, et al. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo. Clin Cancer Res 2006; 12: 2583-90.
153. Bernier SG, Lazarus DD, Clark E, et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004; 101: 10768-73.